N/A N=14,570 Drug Use Investigation of COMIRNATY Intramuscular Injection
COVID-19
Primary: Proportion of Participants With Serious Adverse Events — 0.83 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,474 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale — 219; 188; 197; 119…
Phase 1 N=20 Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib — 21600; 19100; 21000…
N/A N=222 BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007
Prostate Cancer
Primary: Safety Endpoint: Number of Subjects in the Balloon and Control Groups With Rectal, Device or Procedure-related Grade > 1 AEs Within 6 Months of Procedure — 25; 18…
N/A N=23 Neonatal Pulse Oximetry Sensor Study
Premature Birth
Primary: Bland-Altman Analysis for Nellcor Pulse Oximeter — .151; .434 percentage of difference in mean
N/A N=101 Quality of Life After Interventional Thyroid Treatment
Thyroid; Deficiency · Quality of Life
Primary: ThyPRO Scale Scores (0-100, Higher Scores Indicating Worse Quality of Life) — 18.3; 19.9 score — p=<0.001
N/A N=72 Don't Throw Your Heart Away: Clinician Study 3
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
N/A N=55 Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?
Pain Management
Primary: Pain Score — 5; 4.5; 4 units on a scale — p=0.668
N/A N=115 Test Up Now Education Program
Colorectal Cancer Screening
Primary: Number of Participants Up to Date on Colorectal Cancer Screening — 29; 31 Participants — p=<0.05
N/A N=1,019 Don't Throw Your Heart Away: Layperson Study 1
Cardiac Transplant Disorder
Primary: Hospital Choice — 64; 125; 163; 192 Participants
N/A N=514 A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Multiple Myeloma
Primary: Progression Free Survival (PFS): Study C1071003 Cohort A Versus RWD COTA Cohort- Using Unweighted Analysis — NA; 4.70 Months — p=<.0001
Phase 2 N=18 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1
Phase 2 N=211 Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) by BICR Based on IWG Criteria — 78.3; 64.2; 73.3 Percentage of participants
N/A N=105 Don't Throw Your Heart Away: Medical Student Study 2
Cardiac Transplant Disorder
Primary: Hospital Choice — 33; 47; 23; 2 Participants
N/A N=900 HOPE Social Media Intervention for HIV Testing and Studying Social Networks
HIV
Primary: Number of Participants Requesting HIV Self-Testing — 130; 102 Participants